Skip to main content
SpringerLink
Log in

Principles of Radiation Therapy for Hodgkin Lymphoma

  • Chapter
  • First Online:
Book cover Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Radiation therapy (RT) is a major component of the current successful treatment of Hodgkin lymphoma (HL). For decades, radiation was used alone to cure the majority of patients with HL; RT is still the most effective single agent in the oncologic armamentarium for this disease, and RT alone remains the treatment of choice for patients with early-stage lymphocyte predominance HL (LPHL) and for selected patients with classical HL who have contraindications to chemotherapy. Currently, most patients with HL are treated with combined-modality programs in which RT is given as consolidation after chemotherapy. As the role of RT has transformed over the years from a single modality into a component of combined-modality therapy, the classic principles of RT fields, dose, and technique have fundamentally changed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

3DCRT:

Three-dimensional conformal radiotherapy

ABVD:

Adriamycin (doxorubicin) bleomycin, vinblastine, and dacarbazine

AP-PA:

Opposed anterior and posterior fields

ASCT:

Autologous stem cell transplantation

BEACOPP:

Bleomycin etoposide, doxorubicin, cyclophosphamide, procarbazine, prednisone

CR:

Complete response

CT:

Computed tomography

CTV:

Clinical treated

EBVP:

Epirubicin, bleomycin, vinblastine, and dacarbazine

EFS:

Event-free survival

EORTC:

European Organisation for Research and Treatment of Cancer

FFTF:

Freedom from treatment failure

GELA:

Groupe d’Études des Lymphomes Adultes

GHSG:

German Hodgkin Study Group

HL:

Hodgkin lymphoma

IFRT:

Involved-field radiation therapy

IMRT:

Intensity-modulated radiation therapy

INRT:

Involved-node radiation therapy

ISRT:

Involved-site radiation therapy

LPHL:

Lymphocyte-predominant HL

MOP-BAP:

Mechlorethamine, Oncovin [vincristine], prednisone, bleomycin, Adriamycin (doxorubicin), and procarbazine

MOPP:

Mustargen, Oncovin, procarbazine, prednisone

MSKCC:

Memorial Sloan Kettering Cancer Center

NCCN:

National Comprehensive Cancer Network

OS:

Overall survival

PET:

Positron emission tomography

PTV:

Planned treatment volume

RT:

Radiation therapy

STLI:

Subtotal lymphoid irradiation

TLI:

Total lymphoid irradiation

TSH:

Thyroid-stimulating hormone

References

  1. Hoppe RT, Advani R, Ai WZ et al (2012) Hodgkin Lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:589–597

    PubMed  Google Scholar 

  2. Yahalom J (2009) Role of radiation therapy in Hodgkin’s lymphoma. Cancer J 15:155–160

    Article  PubMed  Google Scholar 

  3. Pusey W (1902) Cases of sarcoma and of Hodgkin’s disease treated by exposures to x-rays: a preliminary report. JAMA 38:166–169

    Article  Google Scholar 

  4. Senn N (1903) Therapeutical value of roentgen ray in treatment of pseudoleukemia. N Y Med J 77:665–668

    Google Scholar 

  5. Gilbert R (1925) La roentgentherapie de la granulomatose maligne. J Radiol Electrol 9:509–514

    Google Scholar 

  6. Peters M (1950) A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311

    Google Scholar 

  7. Kaplan H (1962) The radical radiotherapy of Hodgkin’s disease. Radiology 78:553–561

    Article  CAS  PubMed  Google Scholar 

  8. Specht L et al (2014) Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862. doi: 10.1016/j.ijrobp.2013.05.005. Epub 2013 Jun 18

  9. Girinsky T, van der Maazen R et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  10. National Comprehensive Cancer Network Guidelines Version 2 (2014) Hodgkin lymphoma. http://www.nccn.org/

  11. Nogova L, Reineke T, Eich HT et al (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16(10):1683–1687

    Article  CAS  PubMed  Google Scholar 

  12. Wirth A, Yuen K et al (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221–1229

    Article  PubMed  Google Scholar 

  13. Chen RC, Chin MS et al (2010) Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28:136–141

    Article  PubMed  Google Scholar 

  14. Schlembach PJ, Wilder RB et al (2002) Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 8:377–383

    Article  PubMed  Google Scholar 

  15. Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652

    Article  CAS  PubMed  Google Scholar 

  16. Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199–4206

    Article  PubMed  Google Scholar 

  17. Radford J, Barrington S, Counsell N et al (2012) Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial [abstract]. Blood (ASH Ann Meet Abstr) 120(21):|547

    Google Scholar 

  18. Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194. doi: 10.1200/JCO.2013.51.9298. Epub 2014 March 17

  19. Evens AM, Kostakoglu L, (2014) The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Blood 124(23):3356–3364

    Google Scholar 

  20. Herbst C, Rehan FA et al (2009) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. Haematologica 95:494

    Article  PubMed Central  PubMed  Google Scholar 

  21. Loeffler M, Diehl V et al (1997) Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol 15:2275–2287

    CAS  PubMed  Google Scholar 

  22. Aleman BM, Raemaekers JM et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–2406

    Article  PubMed  Google Scholar 

  23. Duggan DB, Petroni GR et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614

    Article  CAS  PubMed  Google Scholar 

  24. Laskar S, Gupta T et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22:62–68

    Article  CAS  PubMed  Google Scholar 

  25. Johnson PWM, Sydes MR, Hancock BW et al (2010) Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial. J Clin Oncol 28:3352–3359

    Article  PubMed  Google Scholar 

  26. Engert A, Haverkamp H, Kobe C et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799

    Article  CAS  PubMed  Google Scholar 

  27. Gordon LI, Hong F, Fisher RI et al (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684–691

    Article  PubMed Central  PubMed  Google Scholar 

  28. Horning SJ, Hoppe RT et al (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637

    Article  PubMed  Google Scholar 

  29. Chisesi T, Federico M et al (2002) ABVD versus stanford V versus MEC in unfavourable Hodgkin’s 9 lymphoma: results of a randomised trial. Ann Oncol 13(Suppl 1):102–106

    Article  PubMed  Google Scholar 

  30. Poen JC, Hoppe RT et al (1996) High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival [see comments]. Int J Radiat Oncol Biol Phys 36:3–12

    Article  CAS  PubMed  Google Scholar 

  31. Yahalom J, Gulati SC et al (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 11:1062–1070

    CAS  PubMed  Google Scholar 

  32. Moskowitz CH, Nimer SD et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’s disease: analysis by intent to treat and development of a prognostic model. Blood 97:617–623

    Article  Google Scholar 

  33. Moskowitz CH, Kewalramani T et al (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 124:645–652

    Article  PubMed  Google Scholar 

  34. Goodman KA, Riedel E et al (2008) Long-term effects of high dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol 26:5240–5247

    Article  PubMed  Google Scholar 

  35. Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13(Suppl 1):79–83

    Article  PubMed  Google Scholar 

  36. Kaplan HS, Rosenberg SA (1966) The treatment of Hodgkin’s disease. Med Clin North Am 50:1591–1610

    CAS  PubMed  Google Scholar 

  37. ICRU. International Commission on Radiation Units and Measurements (1999) Prescribing, recording, and reporting photon therapy. (Supplement to ICRU report 50). ICRU report 62

    Google Scholar 

  38. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, van der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210

    Article  PubMed  Google Scholar 

  39. Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D’Amore F, Boesen AM, Roemer L, Specht L (2006) Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91:482–489

    PubMed  Google Scholar 

  40. Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L (2013) Involved node radiotherapy: an effective alternative in early stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 85:1057–1065

    Article  PubMed  Google Scholar 

  41. Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80:199–205

    Article  PubMed  Google Scholar 

  42. Duhmke E, Franklin J et al (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914

    CAS  PubMed  Google Scholar 

  43. Duhmke E, Diehl V et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310

    Article  CAS  PubMed  Google Scholar 

  44. Prosnitz LR (1976) Radiation doses following intensive chemotherapy in the treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1:803–804

    Article  CAS  PubMed  Google Scholar 

  45. Donaldson SS, Link MP (1987) Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease. J Clin Oncol 5:742–749

    CAS  PubMed  Google Scholar 

  46. Ferme C, Eghbali H et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927

    Article  CAS  PubMed  Google Scholar 

  47. Hodgson DC, Koh ES et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586

    Article  PubMed  Google Scholar 

  48. Kuttesch JF Jr, Wexler LH et al (1996) Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 14:2818–2825

    PubMed  Google Scholar 

  49. Travis LB, Gospodarowicz M et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192

    Article  PubMed  Google Scholar 

  50. Travis LB, Hill D et al (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin’s disease. JAMA 290:465–475

    Article  PubMed  Google Scholar 

  51. van Leeuwen FE, Klokman WJ et al (2002) Effects of radiation dose, chemotherapy, and ovarian hormones on breast cancer risk following Hodgkin’s disease. In: Eighth international conference on malignant lymphoma, Lugano

    Google Scholar 

  52. Koontz B, Kirkpatrick J et al (2006) Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: cure versus complications. J Clin Oncol 24:605–611

    Article  PubMed  Google Scholar 

  53. Salloum E, Doria R et al (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14:2435–2443

    CAS  PubMed  Google Scholar 

  54. Arakelyan N, Jais J-P, Delwall V et al (2010) Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas. Cancer 116:4054–4062

    Article  PubMed  Google Scholar 

  55. Goodman KA, Toner S et al (2005) Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62:198–206

    Article  PubMed  Google Scholar 

  56. Hoppe BS, Flampouri S, Su Z et al (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84(2):449–455

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Joachim Yahalom MD

  2. Department of Radiation Oncology, Stanford University Medical Center, 875 Blake Wilbur Dr, Stanford, CA, 94305, USA

    Richard T. Hoppe MD

Authors
  1. Joachim Yahalom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard T. Hoppe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Yahalom MD .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Yahalom, J., Hoppe, R.T. (2015). Principles of Radiation Therapy for Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation